**Discover How Rezdiffra is Shaping the Future of MASH Treatment
**
Nonalcoholic fatty liver disease and its advanced form, MASH, affect millions of adults—and until recently, treatment options were limited. With the FDA approval of Rezdiffra, the first and only therapy for moderate to advanced MASH, payers and providers are rapidly adapting.

This infographic highlights:

• The growing prevalence of MASH and its clinical impact
• How Rezdiffra is transforming the treatment landscape
• Current payer coverage trends and requirements across top U.S. insurers
• What’s next for the evolving MASH treatment market

Get the data and insights you need to stay ahead in this rapidly changing space.

Request access to view the full infographic to see the coverage landscape and market trends shaping access to Rezdiffra.